
    
      This study is a 12-week, randomised, parallel group, placebo controlled, multi-centre study.
      The primary objective is to evaluate the safety and tolerability of Nutrifriend Cachexia in
      patients with COPD. The secondary objectives of the study are to evaluate effects on body
      composition, muscle function, daily activity, inflammation, lung function, compliance,
      appetite and Quality of Life.
    
  